---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Long-term morbidity"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Long-term morbidity. Topics: Hypertension: incident hypertension in the Wisconsin Sleep Cohort by baseline AHI; Hypertension: cross-sectional association in the Sleep Heart Health Study, hypopnea with 4% desaturation; Cardiovascular disease: prevalence of OSA in cardiovascular conditions, American Heart Association statement; Coronary heart disease and heart failure: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation; 10 further topics. 14 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Hypertension: incident hypertension in the Wisconsin Sleep Cohort by baseline AHI

> “Participants were assessed overnight by 18-channel polysomnography for sleep-disordered breathing, as defined by the apnea-hypopnea index (the number of episodes of apnea and hypopnea per hour of sleep).”
> “Relative to the reference category of an apnea-hypopnea index of 0 events per hour at base line, the odds ratios for the presence of hypertension at follow-up were 1.42 (95 percent confidence interval, 1.13 to 1.78) with an apnea-hypopnea index of 0.1 to 4.9 events per hour at base line as compared with none, 2.03 (95 percent confidence interval, 1.29 to 3.17) with an apnea-hypopnea index of 5.0 to 14.9 events per hour, and 2.89 (95 percent confidence interval, 1.46 to 5.64) with an apnea-hypopnea index of 15.0 or more events per hour.”
> “We found a dose-response association between sleep-disordered breathing at base line and the presence of hypertension four years later that was independent of known confounding factors.”

Source: [Peppard et al. (2000a)](https://pubmed.ncbi.nlm.nih.gov/10805822/)

<a id="topic-2.2.1.7-2"></a>

### Hypertension: cross-sectional association in the Sleep Heart Health Study, hypopnea with 4% desaturation

> “Apnea-hypopnea index (AHI, the average number of apneas plus hypopneas per hour of sleep, with apnea defined as a cessation of airflow and hypopnea defined as a > or = 30% reduction in airflow or thoracoabdominal excursion both of which are accompanied by a > or = 4% drop in oxyhemoglobin saturation) [corrected], obtained by unattended home polysomnography.”
> “After adjusting for demographics and anthropometric variables (including BMI, neck circumference, and waist-to-hip ratio), as well as for alcohol intake and smoking, the odds ratio for hypertension, comparing the highest category of AHI (> or = 30 per hour) with the lowest category (< 1.5 per hour), was 1.37 (95% confidence interval [CI], 1.03-1.83; P for trend = .005).”

Source: [Nieto et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10770144/)

<a id="topic-2.2.1.7-3"></a>

### Cardiovascular disease: prevalence of OSA in cardiovascular conditions, American Heart Association statement

> “OSA prevalence is as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke.”
> “We recommend screening for OSA in patients with resistant/poorly controlled hypertension, pulmonary hypertension, and recurrent atrial fibrillation after either cardioversion or ablation.”

Source: [Yeghiazarians et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34148375/)

<a id="topic-2.2.1.7-4"></a>

### Coronary heart disease and heart failure: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation

> “where both apneas and hypopneas required an associated 4% or greater oxyhemoglobin desaturation”
> “A prospective, longitudinal epidemiologic study of 1927 men and 2495 women aged ≥ 40 years and free of coronary heart disease and heart failure at the time of baseline polysomnography were followed for a median of 8.7 years.”
> “Among men age 40–70 years, those with AHI ≥30 were 68% more likely to develop coronary heart disease than those with AHI <5. OSA predicted incident heart failure in men but not in women (adjusted hazard ratio 1.13 [95% CI 1.02, 1.26] per 10-unit increase in AHI). Men with AHI ≥30 were 58% more likely to develop heart failure than those with AHI <5.”

Source: [Gottlieb et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3117288/)

<a id="topic-2.2.1.7-5"></a>

### Cardiovascular disease: incident events by symptom subtype in the Sleep Heart Health Study

> “Symptom subtype was also associated with incident cardiovascular disease (P < 0.001), coronary heart disease (P = 0.015), and heart failure (P = 0.018), with the excessively sleepy again demonstrating increased risk (hazard ratios, 1.7–2.4) compared with other subtypes.”

Source: [Mazzotti et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6701040/)

<a id="topic-2.2.1.7-6"></a>

### Ischemic stroke: Sleep Heart Health Study, obstructive apnea-hypopnea index

> “A total of 5,422 participants without a history of stroke at the baseline examination and untreated for sleep apnea were followed for a median of 8.7 years. One hundred ninety-three ischemic strokes were observed.”
> “Men in the highest OAHI quartile (>19) had an adjusted hazard ratio of 2.86 (95% confidence interval, 1.1–7.4). In the mild to moderate range (OAHI, 5–25), each one-unit increase in OAHI in men was estimated to increase stroke risk by 6% (95% confidence interval, 2–10%). In women, stroke was not significantly associated with OAHI quartiles, but increased risk was observed at an OAHI greater than 25.”

Source: [Redline et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2913239/)

<a id="topic-2.2.1.7-7"></a>

### Atrial fibrillation and other arrhythmias: Sleep Heart Health Study, respiratory disturbance index of 30 or more

> “(1) 228 subjects with sleep-disordered breathing (respiratory disturbance index ⩾ 30) and (2) 338 subjects without sleep-disordered breathing (respiratory disturbance index < 5).”
> “4.8 versus 0.9% (p = 0.003) for atrial fibrillation; 5.3 versus 1.2% (p = 0.004) for nonsustained ventricular tachycardia; 25.0 versus 14.5% (p = 0.002) for complex ventricular ectopy.”
> “individuals with sleep-disordered breathing had four times the odds of atrial fibrillation (odds ratio [OR], 4.02; 95% confidence interval [CI], 1.03–15.74), three times the odds of nonsustained ventricular tachycardia (OR, 3.40; 95% CI, 1.03–11.20), and almost twice the odds of complex ventricular ectopy (OR, 1.74; 95% CI, 1.11–2.74).”

Source: [Mehra et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2662909/)

<a id="topic-2.2.1.7-8"></a>

### Atrial fibrillation: incident hospitalization in a Western Australian sleep clinic cohort

> “Study case subjects (6,841) were predominantly middle aged (48.3 ± 12.5 years old) and men (77%), and 455 developed AF during a median 11.9 years of follow-up.”
> “After multivariable adjustment, independent predictors of incident AF were an apnea/hypopnea index (AHI) > 5/h (hazard ratio [HR], 1.55; 95% CI, 1.21-2.00), log (AHI + 1) (HR, 1.15; 95% CI, 1.06-1.26), and log (time with oxygen saturation < 90% + 1) (HR, 1.12; 95% CI, 1.06-1.19).”

Source: [Cadby et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25927872/)

<a id="topic-2.2.1.7-9"></a>

### Type 2 diabetes: Wisconsin Sleep Cohort, hypopnea with 4% desaturation

> “A total of 14.7% of subjects with an apnea–hypopnea index (AHI) of 15 or more had a diagnosis of diabetes compared with 2.8% of subjects with an AHI of less than 5.”
> “The odds ratio for developing diabetes mellitus within 4 yr with an AHI of 15 or more compared with an AHI of less than 5 was 1.62 (95% confidence interval, 0.67–3.65; p = 0.24) when adjusting for age, sex, and body habitus.”
> “Although all hypopnea events were marked by oxyhemoglobin desaturation of 4% or greater”

Source: [Reichmuth et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2718458/)

<a id="topic-2.2.1.7-10"></a>

### Type 2 diabetes: meta-analysis of prospective cohort studies

> “This meta-analysis of six prospective cohort studies including a total of 5953 participants, with follow-up periods of 2.7-16 years, and 332 incident cases of type 2 diabetes, showed that moderate-severe OSA was associated with a greater risk of diabetes (RR 1.63; 95% confidence interval (CI): 1.09-2.45), as compared with the absence of OSA.”
> “For subjects with mild OSA, as compared with those without OSA, the pooled RR of developing type 2 diabetes was 1.22 (95% CI: 0.91-1.63).”

Source: [Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22988888/)

<a id="topic-2.2.1.7-11"></a>

### Motor vehicle crashes: systematic review and meta-analysis of crash risk

> “Individuals with OSA are clearly at increased risk for crash. The mean crash-rate ratio associated with OSA is likely to fall within the range of 1.21 to 4.89. Characteristics that may predict crash in drivers with OSA include BMI, apnea plus hypopnea index, oxygen saturation, and possibly daytime sleepiness.”

Source: [Tregear et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792976/)

<a id="topic-2.2.1.7-12"></a>

### Cognitive impairment: mild cognitive impairment or dementia in older women, AHI of 15 or more

> “Sleep disordered breathing was defined as an apnea-hypopnea index of 15 or more events per hour of sleep.”
> “Compared with the 193 women without sleep disordered breathing, the 105 women (35.2%) with SDB were more likely to develop MCI/dementia (n=60 (31.1%) vs n=47 (44.8%)) even after multivariate adjustment (adjusted OR=1.85, 95% CI 1.11-3.08).”

Source: [Yaffe et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3600944/)

<a id="topic-2.2.1.7-13"></a>

### Cognitive impairment: meta-analysis of population-based studies

> “Pooled analysis of the 6 prospective studies indicated that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to develop cognitive impairment, with no evidence of publication bias but significant heterogeneity between studies.”
> “Sleep-disordered breathing was not associated with global cognition or memory.”

Source: [Leng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710301/)

<a id="topic-2.2.1.7-14"></a>

### Cognitive decline: untreated and CPAP-treated older adults with Medicare claims for OSA

> “We analyzed 777 participants from the 2011 National Health and Aging Trends Study (NHATS) with linked Medicare claims, with one or more claims for OSA and no baseline cognitive impairment.”
> “Untreated participants experienced a 69% faster decline”

Source: [Kaufmann et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13366499/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
